Clinical trialsCompany release

Coya completes enrolment in Phase 2/3 ALSTARS ALS trial, topline data due early Q2 2027

🇺🇸 Coya Therapeutics, Inc. (COYA) · Tue 10 Nov 2026

Coya Therapeutics says 137 patients are enrolled in the ALSTARS study of COYA 302, above the 120 planned, as it reports a $10.6 million third-quarter net loss.

Coya Therapeutics has completed enrolment in ALSTARS, its Phase 2/3 trial of COYA 302 in amyotrophic lateral sclerosis (ALS). The company announced the milestone alongside its third-quarter 2026 financial results.

A total of 137 participants were enrolled, compared with the 120 originally planned. The company expects to report 24-week topline data in early Q2 2027, and says it intends to offer an open-label extension.

On the financial side, Coya reported cash of $35.8 million at 30 September 2026. It projects that this will fund operations into the second half of 2027, which is beyond the expected topline readout. The net loss for the quarter was $10.6 million.

The source material available for this report was limited to the company's summary, so further details on trial design, endpoints and the extension study are not covered here.

What it means for your team

  • Topline 24-week data from ALSTARS are guided for early Q2 2027, a date for ALS-focused regulatory and market-access teams to track.
  • Enrolment above the planned 120 participants gives the study a larger safety and efficacy dataset than originally targeted.
  • A planned open-label extension would be expected to generate longer-term safety data, relevant to pharmacovigilance planning.
  • The cash runway into the second half of 2027 covers the expected readout, but the company has not set out further funding plans in the information available.

Company's press release (SEC filing): Coya Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Coya Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →